Australia markets closed
  • ALL ORDS

    7,282.10
    -45.90 (-0.63%)
     
  • AUD/USD

    0.7777
    +0.0019 (+0.25%)
     
  • ASX 200

    7,017.80
    -47.80 (-0.68%)
     
  • OIL

    63.55
    +0.17 (+0.27%)
     
  • GOLD

    1,767.50
    -3.10 (-0.18%)
     
  • BTC-AUD

    71,970.92
    -1,694.00 (-2.30%)
     
  • CMC Crypto 200

    1,265.31
    -33.64 (-2.59%)
     

Parkinson's Disease Drugs: Worldwide Industry Assessment 2020-2027 - ResearchAndMarkets.com

·3-min read

The "Parkinson's Disease Drugs - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Parkinson's Disease Drugs Market to Reach $8.1 Billion by 2027

Amid the COVID-19 crisis, the global market for Parkinson's Disease Drugs estimated at US$ 5.1 Billion in the year 2020, is projected to reach a revised size of US$ 8.1 Billion by 2027, growing at a CAGR of 6.9% over the analysis period 2020-2027.

Oral, one of the segments analyzed in the report, is projected to record a 7.8% CAGR and reach US$ 3.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Injection segment is readjusted to a revised 6.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 10.6% CAGR

The Parkinson's Disease Drugs market in the U.S. is estimated at US$ 1.4 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$ 1.8 Billion by the year 2027 trailing a CAGR of 10.6% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.7% and 6.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Transdermal Segment to Record 5.8% CAGR

In the global Transdermal segment, USA, Canada, Japan, China and Europe will drive the 5.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$ 984.6 Million in the year 2020 will reach a projected size of US$ 1.4 Billion by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$ 1.1 Billion by the year 2027, while Latin America will expand at a 7% CAGR through the analysis period.

Select Competitors (Total 43 Featured):

  • AbbVie Inc.

  • ACADIA Pharmaceuticals

  • Boehringer Ingelheim GmbH

  • GlaxoSmithKline PLC

  • H. Lundbeck A/S

  • Impax Laboratories Inc.

  • M Somerset Pharmaceuticals Inc.

  • Merck & Co. Inc.

  • Mylan N.V.

  • Novartis International AG

  • Orion Pharma

  • Pfizer Inc.

  • Teva Pharmaceuticals Industries Ltd.

  • Vertical Pharmaceuticals

Key Topics Covered

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights

  • World Market Trajectories

  • Impact of COVID-19 and a Looming Global Recession

  • Global Competitor Market Shares

  • Parkinson's Disease Drugs Competitor Market Share Scenario Worldwide (in %): 2020E

  • Global Competitor Market Shares by Segment

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/v0oer8

View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005498/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900